{"url_path":"/sec/jagx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1585608/0001193125-26-232560-index.html","accession_number":"0001193125-26-232560","cik":"0001585608","ticker":"JAGX","issuer_name":"Jaguar Health, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1585608/0001193125-26-232560-index.html","primary_entity_key":"0001585608","primary_entity_name":"Jaguar Health, Inc."},"word_count":1059,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\nExhibit No.\n\n \n\nDescription\n\n3.1\n\n \n\n[Certificate of Designation of Preferences, Rights and Limitations of Series O Convertible Preferred Stock of Jaguar Health, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed March 3, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526086882/d236488d8k.htm)\n\n3.2\n\n \n\n[Certificate of Tenth Amendment of the Third Amended and Restated Certificate of Incorporation of Jaguar Health, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed April 21, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000095017025040784/jagx-ex3_1.htm)\n\n3.3\n\n \n\n[Certificate of Eleventh Amendment of the Third Amended and Restated Certificate of Incorporation of Jaguar Health, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed April 27, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/d109088d8k.htm)\n\n3.4\n\n \n\n[Certificate of Designation of Preferences, Rights and Limitations of Series Q Perpetual Preferred Stock (incorporated by reference to Exhibit 3.1 to the Form 8-K filed May 19, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526231083/d227929d8k.htm)\n\n4.1\n\n \n\n[Form of Unsecured Promissory Note (incorporated by reference to Exhibit 4.1 to the Form 8-K/A filed January 12, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312525019416/d842829dex41.htm)\n\n4.2\n\n \n\n[Form of Common Stock Warrant (incorporated by reference to Exhibit 4.2 to the Form 8-K/A filed January 12, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526010173/jagx-20260106.htm)\n\n4.3\n\n \n\n[Form of the Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Form 8-K filed January 23, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000095017025028403/jagx-ex4_1.htm)\n\n4.4\n\n \n\n[Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Form 8-K filed February 18, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000095017025044842/jagx-ex4_1.htm)\n\n4.5\n\n \n\n[Global Amendment No. 4 dated March 6, 2026, by and between Jaguar Health Inc. and Uptown Capital, LLC (incorporated by reference to Exhibit 4.1 to the Form 8-K filed March 9, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000095017025044842/jagx-ex4_2.htm)\n\n4.6\n\n \n\n[Global Amendment No. 4 dated March 6, 2026, by and between Jaguar Health Inc. and Streeterville Capital, LLC (incorporated by reference to Exhibit 4.2 to the Form 8-K filed March 9, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000095017025044842/jagx-ex4_3.htm)\n\n4.7\n\n \n\n[Amendment to the 2021 Note, dated March 6, 2026, by and among Jaguar Health Inc., Napo Pharmaceuticals, Inc. and Streeterville Capital, LLC (incorporated by reference to Exhibit 4.3 to the Form 8-K filed March 9, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526097700/d89977d8k.htm)\n\n4.8\n\n \n\n[Amendment to the 2025 Note, dated March 6, 2026, by and between Jaguar Health Inc. and Streeterville Capital, LLC (incorporated by reference to Exhibit 4.4 to the Form 8-K filed March 9, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000095017025024228/jagx-ex4_1.htm)\n\n10.1\n\n \n\n[Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Form 8-K/A filed January 12, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526010173/jagx-20260106.htm)\n\n10.2\n\n \n\n[License Agreement, dated January 12, 2026, by and among Napo Pharmaceuticals, Inc., Jaguar Health Inc., Woodward Specialty LLC and Future Pak, LLC (incorporated by reference to Exhibit 10.1 to the Form 8-K filed January 15, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526014231/jagx-20260112.htm)\n\n10.3\n\n \n\n[Supply Agreement, dated January 12, 2026, by and among Napo Pharmaceuticals, Inc., Woodward Specialty LLC and Future Pak, LLC (incorporated by reference to Exhibit 10.2 to the Form 8-K filed January 15, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526014231/jagx-20260112.htm)\n\n10.4\n\n \n\n[Iliad Royalty Interest Exchange Agreement, dated January 16, 2026 (incorporated by reference to Exhibit 10.1 to the Form 8-K filed January 23, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526021064/jagx-20260116.htm)\n\n10.5\n\n \n\n[Streeterville Royalty Interest Exchange Agreement, dated January 16, 2026 (incorporated by reference to Exhibit 10.2 to the Form 8-K filed January 23, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526021064/jagx-20260116.htm)\n\n10.6\n\n \n\n[Iliad Series L Exchange Agreement, dated January 16, 2026 (incorporated by reference to Exhibit 10.3 to the Form 8-K filed January 23, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526021064/jagx-20260116.htm)\n\n10.7\n\n \n\n[Streeterville Series L Exchange Agreement, dated January 16, 2026 (incorporated by reference to Exhibit 10.4 to the Form 8-K filed January 23, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526021064/jagx-20260116.htm)\n\n10.8\n\n \n\n[Iliad Series M Exchange Agreement, dated January 16, 2026 (incorporated by reference to Exhibit 10.5 to the Form 8-K filed January 23, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526021064/jagx-20260116.htm)\n\n10.9\n\n \n\n[Streeterville Series M Exchange Agreement, dated January 16, 2026 (incorporated by reference to Exhibit 10.6 to the Form 8-K filed January 23, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526021064/jagx-20260116.htm)\n\n10.10\n\n \n\n[Security Agreement, dated March 6, 2026, by and between Napo Pharmaceuticals, Inc. and Streeterville Capital, LLC (incorporated by reference to Exhibit 10.1 to the Form 8-K filed March 9, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526097700/d89977d8k.htm)\n\n10.11\n\n \n\n[Warrant Termination Agreement, dated March 6, 2026, by and between Jaguar Health Inc., Uptown Capital, LLC, Streeterville Capital, LLC and Iliad Research and Trading, L.P. (incorporated by reference to Exhibit 10.2 to the Form 8-K filed March 9, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526097700/d89977d8k.htm)\n\n10.12\n\n \n\n[Uptown Series Q Exchange Agreement (incorporated by reference to Exhibit 10.1 to the Form 8-K filed May 19, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526231083/d227929d8k.htm)\n\n10.13\n\n \n\n[First Streeterville Series Q Exchange Agreement (incorporated by reference to Exhibit 10.2 to the Form 8-K filed May 19, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526231083/d227929d8k.htm)\n\n10.14\n\n \n\n[Second Streeterville Series Q Exchange Agreement (incorporated by reference to Exhibit 10.3 to the Form 8-K filed May 19, 2026, File No. 001-36714).](https://www.sec.gov/Archives/edgar/data/1585608/000119312526231083/d227929d8k.htm)\n\n31.1*\n\n \n\n[Principal Executive Officer’s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](jagx-ex31_1.htm)\n\n \n\n80\n\n[Table of Contents](#toc_page)\n\n \n\n31.2*\n\n \n\n[Principal Financial Officer’s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](jagx-ex31_2.htm)\n\n32.1**\n\n \n\n[Certification Pursuant to 18 U.S.C. § 1350 (Section 906 of Sarbanes-Oxley Act of 2002).](jagx-ex32_1.htm)\n\n32.2**\n\n \n\n[Certification Pursuant to 18 U.S.C. § 1350 (Section 906 of Sarbanes-Oxley Act of 2002).](jagx-ex32_2.htm)\n\n101.INS\n\n \n\nInline XBRL Instance Document– the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n104\n\n \n\nThe cover page for the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL and contained in Exhibit 101\n\n \n\n* Filed herewith.\n\n** In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 34 47986, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10 Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 except to the extent that the registrant specifically incorporates it by reference.\n\n \n\n81\n\n[Table of Contents](#toc_page)\n\n \n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nMay 20, 2026\n\n \n\n \n\nJAGUAR HEALTH, INC.\n\n \n\n \n\n \n\n \n\nBy:\n\n/s/ Carol R. Lizak\n\n \n\n \n\nCarol R. Lizak\n\nPrincipal Financial and Accounting Officer\n\n \n\n \n\n82"}